Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 6;10(2):e034103.
doi: 10.1136/bmjopen-2019-034103.

RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study

Affiliations

RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease): study protocol for a multinational, retrospective cohort study

Hyunjin Ryu et al. BMJ Open. .

Abstract

Introduction: Patients with autosomal dominant polycystic kidney disease (ADPKD) reach end-stage renal disease in their fifth decade on average. For effective treatment and early intervention, identifying subgroups with rapid disease progression is important in ADPKD. However, there are no epidemiological data on the clinical manifestations and disease progression of patients with ADPKD from the Asia-Pacific region.

Methods and analysis: The RAPID-ADPKD (Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease) study is a multinational, retrospective, observational cohort study of patients with ADPKD in the Asia-Pacific region (Australia, China, Hong Kong, South Korea, Taipei and Turkey). This study was designed to identify the clinical characteristics of patients with ADPKD with rapid disease progression. Adult patients with ADPKD diagnosed according to the unified ultrasound criteria and with an estimated glomerular filtration rate (eGFR) ≥45 mL/min/1.73 m2 at baseline will be included. The cohort will include patients with ≥2 records of eGFR and at least 24 months of follow-up data. Demographic information, clinical characteristics, comorbidities, medications, eGFR, radiological findings that allow calculation of height-adjusted total kidney volume, ADPKD-related complications and the Predicting Renal Outcomes in autosomal dominant Polycystic Kidney Disease (PRO-PKD) score will be collected. Rapid progression will be defined based on the European Renal Association - European Dialysis and Transplant Association (ERA-EDTA) guideline. All other patients without any of these criteria will be classified to be of slow progression. Clinical characteristics will be compared between patients with rapid progression and those with slow progression. The incidence of complications and the effects of race and water intake on renal progression will also be analysed. The planned sample size of the cohort is 1000 patients, and data from 600 patients have been collected as of 30 May 2019.

Ethics and dissemination: This study was approved or is in the process of approval by the institutional review boards at each participating centre. The results will be presented in conferences and published in a journal, presenting data on the clinical characteristics, risk factors for disease progression and patterns of complications of ADPKD in Asian populations.

Keywords: Asia-Pacific region; autosomal dominant polycystic kidney disease; estimated glomerular filtration rate; height adjusted total kidney volume; rapid progression.

PubMed Disclaimer

Conflict of interest statement

Competing interests: GKR received grant support from Danone Nutricia Research for clinical research on ADPKD.

Figures

Figure 1
Figure 1
Planned structure and data collection in RAPID-ADPKD study. CKD, chronic kidney disease; CKD-EPI, Chronic Kidney Disease Epidemiology Collaboration; ESRD, end-stage renal disease; PKD, polycystic kidney disease; PRO-PKD, Predicting Renal Outcomes in Autosomal Dominant Polycystic Kidney Disease; RAPID-ADPKD, Retrospective epidemiological study of Asia-Pacific patients with rapId Disease progression of Autosomal Dominant Polycystic Kidney Disease.

References

    1. Torres VE, Harris PC, Pirson Y. Autosomal dominant polycystic kidney disease. Lancet 2007;369:1287–301. 10.1016/S0140-6736(07)60601-1 - DOI - PubMed
    1. Torres VE, Harris PC. Autosomal dominant polycystic kidney disease: the last 3 years. Kidney Int 2009;76:149–68. 10.1038/ki.2009.128 - DOI - PMC - PubMed
    1. Hwang Y-H, Conklin J, Chan W, et al. . Refining genotype-phenotype correlation in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2016;27:1861–8. 10.1681/ASN.2015060648 - DOI - PMC - PubMed
    1. Chapman AB, Devuyst O, Eckardt K-U, et al. . Autosomal-Dominant polycystic kidney disease (ADPKD): Executive summary from a kidney disease: improving global outcomes (KDIGO) controversies conference. Kidney Int 2015;88:17–27. 10.1038/ki.2015.59 - DOI - PMC - PubMed
    1. Gansevoort RT, Arici M, Benzing T, et al. . Recommendations for the use of tolvaptan in autosomal dominant polycystic kidney disease: a position statement on behalf of the ERA-EDTA working groups on inherited kidney disorders and European renal best practice. Nephrol Dial Transplant 2016;31:337–48. 10.1093/ndt/gfv456 - DOI - PMC - PubMed

Publication types